Industry Symposia
Thursday, October 26, 2017
| 17:30-19:00 Hall 1 |
Industry Symposium: The 21 Gene Assay: The Evidence in 2017 Supported by Genomic Health |
 |
Friday, October 27, 2017
| 08:00-09:00 Hall 1 |
Morning Industry Symposium: Comprehensive genomic sequencing for breast cancer patients in Japan Supported by Denka-KEW Genomics |
 |
| 12:45-13:45 Hall 1 |
Luncheon Industry Symposium: The tumor microenvironment in breast cancer progression: Clinical implications for OS benefit Supported by Eisai |
 |
| 12:45-13:45 Hall 2 |
Luncheon Industry Symposium: Current situation and future perspective of HBOC practice in Japan Supported by AstraZeneca |
 |
| 17:00-18:30 Hall 1 |
Industry Symposium: New treatment strategy for HR-positive and HER2 negative metastatic breast cancer patients Supported by Pfizer |
 |
Saturday, October 28, 2017
| 08:30-09:30 Hall 2 |
Morning Industry Symposium: Treatment strategy for HER2-positive metastatic breast cancer Supported by Chugai |
 |
| 13:15-14:15 Hall 1 |
Luncheon Industry Symposium: Future perspective of oral-FU drug in the management of breast cancer Supported by Taiho |
 |
| 13:15-14:15 Hall 2 |
Luncheon Industry Symposium: What needs to perform chemotherapy for breast cancer in the current era? Supported by Kyowa Kirin |
 |